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Risk of bias in studies on prediction models developed using 
supervised machine learning techniques: systematic review
Constanza L Andaur Navarro,1,2 Johanna A A Damen,1,2 Toshihiko Takada,1 Steven W J Nijman,1 




To assess the methodological quality of studies on 
prediction models developed using machine learning 




PubMed from 1 January 2018 to 31 December 2019.
ELIGIBILITY CRITERIA
Articles reporting on the development, with or without 
external validation, of a multivariable prediction 
model (diagnostic or prognostic) developed using 
supervised machine learning for individualised 
predictions. No restrictions applied for study design, 
data source, or predicted patient related health 
outcomes.
REVIEW METHODS
Methodological quality of the studies was determined 
and risk of bias evaluated using the prediction risk of 
bias assessment tool (PROBAST). This tool contains 
21 signalling questions tailored to identify potential 
biases in four domains. Risk of bias was measured for 
each domain (participants, predictors, outcome, and 
analysis) and each study (overall).
RESULTS
152 studies were included: 58 (38%) included 
a diagnostic prediction model and 94 (62%) a 
prognostic prediction model. PROBAST was applied to 
152 developed models and 19 external validations. 
Of these 171 analyses, 148 (87%, 95% confidence 
interval 81% to 91%) were rated at high risk of bias. 
The analysis domain was most frequently rated at 
high risk of bias. Of the 152 models, 85 (56%, 48% 
to 64%) were developed with an inadequate number 
of events per candidate predictor, 62 handled 
missing data inadequately (41%, 33% to 49%), and 
59 assessed overfitting improperly (39%, 31% to 
47%). Most models used appropriate data sources to 
develop (73%, 66% to 79%) and externally validate 
the machine learning based prediction models (74%, 
51% to 88%). Information about blinding of outcome 
and blinding of predictors was, however, absent in 60 
(40%, 32% to 47%) and 79 (52%, 44% to 60%) of the 
developed models, respectively.
CONCLUSION
Most studies on machine learning based prediction 
models show poor methodological quality and are at 
high risk of bias. Factors contributing to risk of bias 
include small study size, poor handling of missing 
data, and failure to deal with overfitting. Efforts to 
improve the design, conduct, reporting, and validation 
of such studies are necessary to boost the application 





A multivariable prediction model is defined as any 
combination of two or more predictors (variables, 
features) for estimating the probability or risk of an 
individual having (diagnosis) or developing (prognosis) 
a particular outcome.1-4 Properly conducted and well 
reported prediction model studies are essential for the 
correct implementation of models in clinical practice. 
Despite an abundance of studies on prediction models, 
only a limited number of these models are used in 
clinical practice. As such, many published studies 
contribute to research waste.5 We anticipate that the 
rise of modern data driven modelling techniques will 
boost the existing popularity of prediction model 
studies in the biomedical literature.6 7
Machine learning, a subset of artificial intelligence, 
has gained considerable popularity in recent years. 
Broadly, machine learning refers to computationally 
intensive methods that use data driven approaches to 
develop models that require fewer modelling decisions 
by the modeller compared with traditional modelling 
techniques.8-11 Machine learning comprises the two 
approaches of supervised and unsupervised learning. 
In the former an algorithm learns to make predictions 
using previously labelled outcomes, whereas in 
the latter the algorithm learns to find unexpected 
patterns using unlabelled outcomes.12 Traditional 
prediction models in healthcare usually resemble 
the supervised learning approach: datasets used for 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Several publications have highlighted the poor methodological quality of 
regression based prediction model studies
The number of clinical prediction models developed using supervised machine 
learning is rapidly increasing; however, evidence about methodological quality 
and risk of bias is scarce
WHAT THIS STUDY ADDS
Prediction model studies developed using supervised machine learning have 
poor methodological quality
Limited sample size, poor handling of missing data, and inappropriate 
evaluation of overfitting contributed largely to the overall high risk of bias
Predictive performance reported on studies may be at high risk of bias, thus 
caution is needed when interpreting these findings
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model development are labelled and the objective 
is to predict an outcome in new data. Examples of 
supervised learning include random forest, naïve 
bayes, gradient boosting machines, support vector 
machines, and neural networks. Studies on supervised 
machine learning based prediction models have 
shown promising and even superior predictive 
performance compared with conventional statistical 
techniques; however, recent systematic reviews have 
shown otherwise.13-16 Although several publications 
have raised concern about the methodological quality 
of prediction models developed with conventional 
statistical techniques,6 17 18 a formal methodological 
and risk of bias assessment of supervised machine 
learning based prediction model studies across all 
medical disciplines have not yet been carried out.
Shortcomings in study design, methods, conduct, 
and analysis might set the study at high risk of bias, 
which could lead to deviated estimates of the models’ 
predictive performance.19 20 The prediction model risk 
of bias assessment tool (PROBAST) was developed to 
facilitate risk of bias assessment and thus provides a 
methodological quality assessment of primary studies 
that report on development, validation, or update of 
prediction models, regardless of the clinical domain, 
predictors, outcomes, or modelling technique used.19 20 
Using a prediction model considered at high risk of bias 
might lead to unnecessary or insufficient interventions 
and thus affect patients’ health and health systems. 
Rigorous risk of bias evaluation of prediction model 
studies is therefore essential to ensure reliable, fast, 
and valuable application of prediction models.
We conducted a systematic review to assess the 
methodological quality and risk of bias of studies on 
supervised machine learning based prediction models 
across all medical specialties in a contemporary 
sample of the literature.
Methods
Our systematic review was reported following the 
preferred reporting items for systematic reviews and 
meta-analyses statement.21 The review protocol was 
registered and has been published.22
Identification of prediction model studies
On 19 December 2019, we searched for eligible 
studies published in PubMed from 1 January 2018 
to 31 December 2019 (see supplementary file 1 for 
search strategy). We restricted our search to obtain a 
contemporary sample of articles that would reflect 
current practices in prediction modelling using 
machine learning. 
Eligible publications needed to describe the 
development or validation of at least one multivariable 
prediction model using any supervised machine 
learning technique that aimed for individualised 
prediction of risk of patient related health outcomes. 
Our protocol lists the inclusion and exclusion 
criteria.22 A study was also considered eligible if it 
aimed to develop a prediction model based on model 
extension or incremental value of new predictors. No 
restrictions were applied based on study design, data 
source, or types of patient related health outcomes. We 
defined a study to be an instance of machine learning 
when a non-regression statistical technique was used 
to develop or validate a prediction model. Therefore we 
excluded studies using only linear regression, logistic 
regression, lasso regression, ridge regression, or elastic 
net. Publications that reported the association of a 
single predictor, test, or biomarker, or its causality, with 
an outcome were also excluded, as were publications 
that aimed to use machine learning to enhance the 
reading of images or signals or those where machine 
learning models only used genetic traits or molecular 
markers as predictors. Other exclusions were systematic 
reviews, methodological articles, conference abstracts, 
and publications for which full text was unavailable 
through our institution. We restricted our search to 
studies in human participants and articles written in 
English.
Screening process
Two independent reviewers, from a group of seven 
(CLAN, TT, SWJN, PD, JM, RB, and JAAD), screened 
titles and abstracts. A third reviewer helped to 
resolve disagreements (JAAD). After potentially 
eligible studies had been selected, two independent 
researchers reviewed the retrieved full text articles for 
eligibility; one researcher (CLAN) screened all articles, 
and six researchers (TT, SWJN, PD, JM, RB, and JAAD) 
collectively screened the same articles for agreement. 
A third reviewer (JAAD) read articles to resolve 
disagreements.
Data extraction
We developed a data extraction form based on the 
four domains: participants, predictors, outcome, and 
analysis (box) as well as 20 signalling questions as 
described in PROBAST.19 20
Our extraction form contained three sections for 
each domain: two to nine specific signalling questions, 
judgment of risk of bias, and rationale for the judgment. 
Signalling questions were formulated to be answered 
as yes or probably yes, no or probably no, and no 
information. The signalling questions were phrased so 
that yes or probably yes indicated an absence of bias. 
Likewise, judgment of risk of bias was defined as high, 
low, or unclear risk of bias. Also, reviewers provided a 
rationale for judgment as free text comments.
If a study included external validation, we applied 
the extraction form to both the development and the 
external validation of the model. Signalling question 
4.5, “Was selection of predictors based on univariable 
analysis avoided?; 4.8 “Were model overfitting and 
optimism in model performance accounted for?”; 
and 4.9 “Do predictors and their assigned weights 
in the final model correspond to the results from the 
reported multivariable analysis?” did not apply to 
external validation. If a study reported more than one 
model, we applied PROBAST to the recommended 
model defined by the authors in the article. If the 
authors did not recommend a model, we selected the 
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one with highest accuracy (in terms of discrimination) 
as the recommended model. The PROBAST tool, 
its considerations, and related publications are 
available on the PROBAST website (www.probast.org). 
Supplementary file 2A provides a summary table with 
the criteria used to judge risk of bias.
Two reviewers independently extracted data 
from each article using the constructed form. To 
ensure consistent data extraction by all reviewers, 
we piloted the form on five articles. During the pilot, 
reviewers clarified differences in interpretation and the 
standardised data extraction. After the pilot, articles 
used were randomly assigned and screened again 
during the main data extraction. One researcher (CLAN) 
extracted data from all articles, and six researchers 
(TT, SWJN, PD, JM, RB, and JAAD) collectively extracted 
data from the same articles. Any disagreements in data 
extraction were settled by consensus among each pair 
of reviewers.
Data analysis
Prediction model studies were categorised as prognosis 
or diagnosis and subcategorised into four types 
of prediction models: development (with internal 
validation), development with external validation 
(same model), development with external validation 
(another model), and external validation only.19 20
Model development studies with internal validation—
these studies aim to develop a prediction model to be 
used for individualised predictions where its predictive 
performance is directly evaluated using the same data, 
either by resampling participant data or random or 
non-random split sample (internal validation).
Model development studies with external validation 
of the same model—these studies have the same aim 
as the model development studies, but the predictive 
performance of the model is subsequently quantified 
in a different dataset.
Model development studies with external validation 
of another model—these studies aim to update or adjust 
an existing model that performs poorly by recalibrating 
or extending the model.
External validation only studies—these studies 
aim to assess only the predictive performance of 
existing prediction models using data external to the 
development sample.
Two independent reviewers each assessed the 
signalling questions by the degree of compliance 
with the PROBAST recommendations. Disagreements 
were discussed until consensus was reached. The risk 
of bias judgment for each domain was based on the 
answers to the signalling questions. If the answer to 
all signalling questions was yes or probably yes, then 
the domain was judged as low risk of bias. If reported 
information was insufficient to answer the signalling 
questions, these were judged as no information, and 
the domain was scored as unclear risk of bias. If any 
signalling question was answered as no or probably 
no, the reviewers applied their judgment to rate the 
domain as low, high, or unclear risk of bias.
After judging all the domains, we performed an 
overall assessment for each application of PROBAST. 
This tool recommends rating the study as low risk 
of bias if all domains had low risk of bias. If at least 
one domain had a high risk of bias, overall judgment 
should be rated as high risk of bias. If the risk of bias 
was unclear in at least one domain and all other 
domains had a low risk of bias then an unclear risk 
of bias was assigned. The rationale behind judgments 
was recorded to facilitate discussion among reviewers 
when solving discrepancies. We removed signalling 
question 4.9, “Do predictors and their assigned 
weights in the final model correspond to the results 
from the reported multivariable analysis?” because 
it applies to regression based studies. Results were 
summarised as percentages with corresponding 95% 
confidence intervals and visual plots. Analyses were 
performed using R version 3.6.2 (R Core Team, 2020).
Patient and public involvement
It was not possible to involve participants or the public 
in setting the research question nor were they involved 
in the design or implementation of the study or the 
interpretation or writing up of results. The protocol 
is available open access https://bmjopen.bmj.com/
content/10/11/e038832.
Results
The search identified 24 814 articles, of which 10 
random sets of 249 publications each were sampled. 
Of the 2482 screened articles, 152 studies were eligible 
(see supplementary file 3 for details of the studies): 
94 (62%) were prognostic and 58 (38%) diagnostic 
studies of machine learning based prediction models 
(fig 1). The articles were classified according to the aims 
of the research: 132 (87%) as model development with 
internal validation, 19 (13%) as model development 
with external validation of the same model, and 1 
(1%) as model development with external validation 
of another model (eventually included as development 
with internal validation). Across the 152 studies, a total 
of 1429 machine learning based prediction models 
were developed and 219 validated. For the analyses in 
the current study, only the model recommended by the 
authors was selected for the risk of bias assessment. 
Box 1: Description of domains used in data extraction form
Participants domain
• Covers potential biases related to the selection of participants and data sources 
used
Predictors domain
• Evaluates potential sources of bias from the definition and measurement of the 
candidate predictors
Outcome domain
• Assesses how and when the outcome was defined and determined
Analysis domain
• Examines the statistical methods that authors have used to develop and validate the 
model, including study size, handling of continuous predictors and missing data, 
selection of predictors, and model performance measures
 on 28 O












J: first published as 10.1136/bm






4 doi: 10.1136/bmj.n2281 | BMJ 2021;375:n2281 | the bmj
Hence PROBAST was applied 171 times: in 152 
developed models and 19 external validations. The 
most common machine learning techniques for the 
first model reported were classification and regression 
tree (10.1%), support vector machine (9.4%), and 
random forest (9.4%). Supplementary file 3 provides 
a detailed list of the techlniques assessed. The clinical 
specialties with the most publications were oncology 
(21/152, 14%), surgery (20/152, 14%), and neurology 
(20/152, 14%).
Participants domain
In total, 36/152 (24%) developed models and 3/19 
(16%) external validations were rated as high risk of 
bias for the participants domain (fig 2). Prospective 
and longitudinal data sources (signalling question 1.1) 
were properly used for model development in 111/152 
(73%) and for external validation in 14/19 (74%). It 
was not possible to evaluate whether the inclusion 
and exclusion of participants (signalling question 1.2) 
was representative of the target population in 47/152 
(31%) developed models and 12/19 (63%) external 
validations (table 1).
Predictors domain
Overall, 14/152 (9%) developed models and 2/19 (11%) 
external validations were rated as high risk of bias for 
the predictors domain (fig 2). Candidate predictors were 
defined and assessed in a similar way for all included 
participants (signalling question 2.1) in 109/152 (72%) 
developed models and 8/19 (42%) external validations. 
Information on blinding of predictor assessment to 
outcome data (signalling question 2.2) was missing 
in 60/152 (40%) developed models and 7/19 (37%) 
external validations. All the considered predictors 
should be available at the time the model is intended to 
be used (signalling question 2.3), which was considered 
appropriate in 116/152 (77%) developed models and 
12/19 (63%) external validations (table 1).
Outcome domain
The outcome domain was rated as unclear risk of 
bias in 65/152 (43%) developed models and 12/19 
(63%) external validations (fig 2). Information was 
missing about the outcome being determined without 
knowledge of predictors’ information (signalling 
question Q3.5) in 79/152 (52%) developed models 
and 14/19 (74%) external validations. Predictors 
were excluded from the outcome definition (signalling 
question 3.3) in 90/152 (59%) developed models and 
10/19 (53%) external validations. The time interval 
between predictor measurement and determination 
of outcome was considered appropriate (signalling 
question 3.6) in 110/152 (72%) developed models 
and 11/19 (58%) external validations. In 114/152 
(75%) developed models and 12/19 (63%) 
external validations, the outcome was determined 
using appropriate methods, thus reducing risk of 
misclassification (signalling question 3.1). Similarly, 
118/152 (78%) developed models and 13/19 (68%) 
external validations used prespecified, standard, or 
consensus based definitions to determine the outcome 
(signalling question 3.2). The outcome was defined 
and measured with the same categories or thresholds 
for all included participants (signalling question 3.4) 
in 118/152 (78%) developed models and 10/19 (53%) 
external validations (table 1).
Analysis domain
Overall, 128/152 (84%) developed models and 
14/19 (74%) external validations were rated as high 
risk of bias in the analysis domain. The number of 
participants with the outcome (signalling question 
4.1) was considered insufficient (ie, event per predictor 
parameter <10) in 85/152 (56%) developed models 
and 8/19 (42%) external validations (ie, number of 
events <100). Information about methods to handle 
continuous and categorical predictors (signalling 
question 4.2) was missed in 81/152 (53%) developed 
models and 18/19 (95%) external validations. In total, 
84/152 (55%) developed models and 10/19 (53%) 
external validations included in the statistical analyses 
all enrolled participants (signalling question 4.3).
Handling of missing data (signalling question 4.4) 
was inappropriate (ie, participants with missing data 
Excluded
Non-human participants
No prediction model studies
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Fig 1 | Flowchart of included studies
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were omitted from the analysis or the imputation 
method was flawed) in 62/152 (41%) developed models 
and 7/19 (37%) external validations. Overall, 28/152 
(18%) developed models used univariable analyses to 
select predictors (signalling question 4.5). It was not 
possible to assess if censoring, competing risks, or 
sampling of control participants (signalling question 
4.6) was considered in 54/152 (36%) developed 
models and 7/19 (37%) external validations. Similarly, 
the reporting of relevant model performance measures 
(eg, both discrimination and calibration) (signalling 
question 4.7) was missing in 91/152 (60%) developed 
models and 13/19 (68%) external validations. Seventy 
six (50%) developed models accounted for model 
overfitting and optimism (signalling question 4.8).
Overall risk of bias
The overall risk of bias assessed using PROBAST 
resulted in 133/152 (88%) developed models and 
15/19 (79%) external validations being rated as high 
risk of bias (fig 2). Table 1 shows further information 
about each signalling question answered as yes or 
probably yes, no or probably no, and no information.
Diagnostic versus prognostic models
The analysis domain was the major contributor to an 
overall high risk of bias in both the diagnostic and the 
prognostic prediction models. Overall, 56/58 (97%) 
developed models and 7/7 (100%) external validations 
were evaluated as high risk of bias in diagnostic 
studies, and 77/94 (82%) developed models and 8/13 
(67%) external validations in prognostic studies (fig 2). 
External validations of both diagnostic and prognostic 
models are prone to unclear information to judge 
risk of bias. While for diagnostic models, signalling 
questions in the outcome domain were frequently 
answered with no information (supplementary table 
S2), for prognostic models this was the case for 
both the outcome domain and the analysis domain 
(supplementary table S3). Supplementary file 3 
provides further information about each signalling 
question.
Diagnosis external validation (n=7)
Prognosis external validation (n=12)
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Fig 2 | Risk of bias of included studies (n=152) and stratified by study type
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Discussion
In this study we assessed the methodological quality 
of studies on supervised machine learning based 
prediction models across all clinical specialties. 
Overall, 133/152 (88%) developed models and 15/19 
(79%) external validations showed high risk of bias. 
The analysis domain was most commonly rated as 
high risk of bias in developed models and external 
validations, mainly as a result of low number of 
participants with the outcome (relative to the number 
of candidate predictors), risk of overfitting, and 
inappropriate handling of participants with missing 
Table 1 | PROBAST signalling questions for model development and validation analyses in 152 included studies. Values are number, percentage (95% 
confidence interval)
Signalling 
question No Signalling question
Developed models (n=152) External validations (n=19)
Yes or probably yes No or probably no No information Yes or probably yes No or probably no No information
Participants domain
1.1
Were appropriate data sources 
used, for example, cohort, 
randomised controlled trial, or 
nested case-control study data?
111 (73, 66 to 79) 32 (21, 15 to 28) 9 (6, 3 to 11) 14 (74, 51 to 88) 5 (26, 12 to 49) 0
1.2
Were all inclusions and 
exclusions of participants 
appropriate?
89 (59, 51 to 66) 16 (11, 7 to 16) 47 (31, 24 to 39) 7 (37, 19 to 59) 0 12 (63, 41 to 81)
Predictors domain
2.1
Were predictors defined and 
assessed in a similar way for all 
participants?
109 (72, 64 to 78) 19 (13, 8 to 19) 24 (16, 11 to 22) 8 (42, 23 to 64) 1 (5, 0 to 25) 10 (53, 32 to 73)
2.2
Were predictor assessments 
made without knowledge of 
outcome data?
88 (58, 50 to 66) 4 (3, 1 to 7) 60 (40, 32 to 47) 10 (53, 32 to 73) 2 (11, 3 to 31) 7 (37, 19 to 59)
2.3
Were all predictors available at 
the time the model was intended 
to be used?
117 (77, 70 to 83) 4 (3, 1 to 7) 31 (20, 15 to 28) 12 (63, 41 to 81) 1 (5, 0 to 25) 6 (32, 15 to 54)
Outcome domain
3.1 Was the outcome determined appropriately? 114 (75, 68 to 81) 6 (4, 2 to 8) 32 (21, 15 to 28) 12 (63, 41 to 81) 0 7 (37, 19 to 6)
3.2 Was a prespecified or standard outcome definition used? 118 (78, 70 to 84) 6 (4, 2 to 8) 28 (18, 13 to 25) 13 (68, 46 to 85) 0 6 (32, 15 to 54)
3.3 Were predictors excluded from the outcome definition? 90 (59, 51 to 67) 8 (5, 3 to 1) 54 (36, 28 to 43) 10 (53, 32 to 73) 0 9 (47, 27 to 69)
3.4
Was the outcome defined and 
determined in a similar way for 
all participants?
118 (78, 70 to 84) 11 (7, 4 to 13) 23 (15, 10 to 22) 10 (53, 32 to 73) 1 (5, 0 to 25) 8 (42, 23 to 64)
3.5
Was the outcome determined 
without knowledge of predictor 
information?
63 (41, 34 to 49) 10 (7, 4 to 12) 79 (52, 44 to 60) 4 (21, 9 to 43) 1 (5, 0 to 25) 14 (74, 51 to 88)
3.6
Was the time interval between 
predictor assessment and 
outcome determination?
110 (72, 65 to 79) 2 (1, 0 to 5) 40 (26, 20 to 34) 11 (60, 36 to 77) 1 (5, 0 to 25) 7 (37, 19 to 59)
Analysis domain
4.1
Were there a reasonable 
number of participants with the 
outcome?
52 (34, 27 to 42) 85 (56, 48 to 64) 15 (10, 6 to 16) 8 (42, 23 to 64) 8 (42, 23 to 64) 3 (16, 6 to 38)
4.2
Were continuous and 
categorical predictors handled 
appropriately?
37 (24, 18 to 32) 34 (22, 17 to 30) 81 (53, 45 to 61) 0 1 (5, 0 to 25) 18 (95, 75 to 100)
4.3 Were all enrolled participants included in the analysis? 84 (55, 47 to 63) 29 (19., 14 to 26) 39 (26, 19 to 33) 10 (53, 32 to 73) 3 (16, 6 to 38) 6 (32, 15 to 54)
4.4 Were participants with missing data handled appropriately? 20 (13, 9 to 20) 62 (41, 33 to 49) 70 (46, 38 to 54) 3 (16, 6 to 38) 7 (37, 19 to 59) 9 (47, 27 to 68)
4.5
Was selection of predictors 
based on univariable analysis 
avoided?
101 (66, 59 to 74) 28 (18, 13 to 25) 23 (15., 10 to 22) NA
4.6
Were complexities in the data 
(e.g., censoring, competing risks, 
sampling of control participants) 
accounted for appropriately?
63 (41, 34 to 49) 35 (23, 17 to 30) 54 (36, 28 to 43) 8 (42, 23 to 64) 4 (21, 9 to 43) 7 (37, 19 to 59)
4.7
Were relevant model 
performance measures 
evaluated appropriately?
15 (10, 6 to 16) 46 (30, 24 to 38) 91 (60, 52 to 67) 3 (16, 6 to 38) 3 (16, 6 to 38) 13 (68, 46 to 85)
4.8
Were model overfitting and 
optimism in model performance 
accounted for?
76 (50, 42 to 58) 59 (39, 31 to 47) 17 (11, 7 to 17) NA
Signalling question 4.9 “Do predictors and their assigned weights in the final model correspond to the results from the reported multivariable analysis?” was not included as it applies to 
regression based studies.
PROBAST=prediction risk of bias assessment tool; NA=not applicable to external validation.
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data. Although no studies are conclusive about sample 
size calculations for developing prediction models 
using machine learning techniques, these studies 
usually require (many) more participants and events 
than do conventional statistical approaches.23 24 One 
hundred studies failed to either provide the number of 
events or report an event per candidate predictor lower 
than 10, which historically is a marker of potentially low 
sample size. Furthermore, machine learning studies 
with a low number of participants with the outcome 
are prone to overfitting—that is, the model is too much 
tailored to the development dataset.23-26 Only half of 
the included studies examined potential overfitting 
of models by using either split data, bootstrapping, 
or cross validation. Random split was often relied on 
to internally validate models (ie, validation based on 
the same participants’ data), whereas bootstrapping 
and cross validation are generally considered more 
appropriate.27
Most studies carried out complete case analyses 
or imputation using means or medians. Multiple 
imputation is generally preferred as it prevents biased 
model performance as a result of deletion or single 
imputation of participants’ missing data. Multiple 
imputation is, however, still unpopular within models 
developed with machine learning techniques.28 29 
Some machine learning techniques have the power to 
incorporate this missingness by including a separate 
category of a predictor variable that has missing 
values.30 Therefore, it would be useful if algorithm 
developers could improve imputation methods and 
incorporate informative missingness in their models 
when possible.
Several signalling questions were scored as “no 
information”, making it impossible for us to judge 
potential biases. It was often unclear whether all 
enrolled participants were included in the analyses, 
how many participants had missing values, and how 
missing data were handled. Machine learning is a 
powerful and automated technique that will learn 
from data; however, if selection bias is present in the 
dataset, predictions made using the trained machine 
learning algorithm will also be biased. Similarly, 
several signalling questions in PROBAST are tailored 
to identify lack of blinding (signalling questions 2.2, 
3.3, and 3.5); however, almost half of included articles 
failed to report any information for us to assess blinding. 
Furthermore, model calibration tables or plots were 
often not presented, whereas classification measures 
(ie, confusion matrix) were commonly reported with an 
overreliance on accuracy.31 Reporting and assessment 
of discrimination (the ability to discriminate between 
cases and non-cases) and calibration (agreement 
between predictions and observed outcomes) are 
essential to assess a models’ predictive performance.31
Comparison with other studies
A systematic review of 23 studies about machine 
learning for diagnostic and prognostic predictions 
in emergency departments found that analysis was 
the most poorly rated domain, with 20 studies at 
high risk of bias.32 This study found deficiencies in 
how continuous variables and missing data were 
handled, and that model calibration was rarely 
reported. Another publication about machine 
learning risk prediction models for triage of patients 
in the emergency department also considered 22/25 
studies at high risk of bias.33 A study assessing the 
performance of diagnostic deep learning algorithms 
for medical imaging reported 58 of 81 studies classified 
as overall high risk of bias.7 Similar to our results, 
major deficiencies were found in the analysis domain 
including the number of events per variable, inclusion 
of enrolled participants in the analysis, reporting of 
relevant model performance measures, and overfitting. 
Recently, a living systematic review about covid-19 
prediction models indicated that all 57 studies that 
used machine learning were at high risk of bias owing 
to insufficient sample size, unreported calibration, and 
internal validation based on training-test split.34
Strength and limitations of this study
We evaluated the risk of bias of supervised machine 
learning based prediction model studies in a broad 
sample of articles that included prognostic and 
diagnostic development only and development 
with external validation studies. After using a 
validated search strategy, we retrieved nearly 25 000 
publications, which is similar to a previous study.35 
We only screened one 10th of these articles; therefore, 
our results are presented using confidence intervals 
to extrapolate them to the whole sample. The present 
analyses considered results from studies that were 
published more than one year ago; nevertheless, 
we expect these findings still to be applicable and 
relevant for the clinical prediction specialty. We 
adopted PROBAST as the benchmark for evaluating 
risk of bias, enhancing the objectivity and consistency; 
however, this is not without certain limitations. While 
two signalling question in PROBAST might become 
less relevant within the machine learning context (ie, 
selection of predictors based on univariable analysis 
and reporting of weighted estimates in the final 
model correspond to the results from the reported 
multivariable analysis), further signalling questions 
related to data generation, feature selection, and 
overfitting might be necessary.
Implication for researchers, editorial offices, and 
future research
The number of machine learning based studies is 
increasing every year; thus, their identification, 
reporting, and assessment become even more 
relevant. It will remain a challenge to determine 
the risk of bias if detailed information about data 
and modelling approach (including justifications 
to any decision made that may biases estimates) 
is not clearly reported in articles. To better judge 
studies, we recommend that researchers adhere to the 
transparent reporting of a multivariable prediction 
model for individual prognosis or diagnosis (TRIPOD) 
statement.36 37 Although TRIPOD was not explicitly 
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developed for machine learning prediction models, 
all items are applicable. Similarly, while there is yet 
no risk of bias assessment tool available specifically 
for supervised machine learning models, we suggest 
researchers follow PROBAST recommendations to 
reduce potential biases when planning and modelling 
primary prediction models using either regression or 
non-regression models. For example, the adoption 
of multiple imputation to handle missing values and 
cross validation or bootstrapping to internally validate 
the developed models.
Currently, extensions of TRIPOD and PROBAST for 
prediction models developed using machine learning 
are under development (TRIPOD-AI, PROBAST-AI).38 39 
As sample size contributed largely to the overall high 
risk of bias, future methodological research could 
focus on determining the appropriate sample sizes 
for each supervised learning technique. Giving the 
rapid and constant evolution of machine learning, 
periodic systematic reviews of prediction model 
studies need to be conducted. Although high quality 
machine learning based prediction model studies 
are scarce, those that stand out need to be validated, 
recalibrated, and promptly implemented in clinical 
practice.34 To avoid research waste, we suggest that 
peer reviewers and journal’s editors promote the 
adherence to reporting guidelines.5 Facilitating the 
documentation of studies (ie, supplementary material, 
data, and code) and setting an unlimited word count 
might improve methodological quality assessment, 
as well as independent validation (ie, replication). 
Likewise, requesting external validation of prediction 
models upon submission might help to set minimum 
standards to ensure generalisability of supervised 
machine learning based prediction models studies.
Conclusion
Most studies on prediction models developed using 
machine learning show poor methodological quality 
and are at high risk of bias. Factors contributing to 
the risk of bias include the exclusion of participants, 
small sample size, poor handling of missing data, and 
failure to address overfitting. Efforts to improve the 
design, conduct, reporting, and validation studies of 
supervised machine learning based prediction models 
are necessary to boost its application in clinical 
practice and avoid research waste.
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